Home » Stocks » AbbVie

AbbVie Inc. (ABBV)

Stock Price: $96.91 USD -1.03 (-1.05%)
Updated Jul 10, 2020 11:00 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 170.79B
Revenue (ttm) 34.06B
Net Income (ttm) 8.44B
Shares Out 1.76B
EPS (ttm) 5.65
PE Ratio 17.15
Forward PE 10.14
Dividend $4.72
Dividend Yield 4.87%

Stock Quote

Trading Day Jul 10, 2020
Last Price $96.91
Previous Close $97.94
Change ($) -1.03
Change (%) -1.05%
Day's Open 98.06
Day's Range 96.40 - 98.33
Day's Volume 1,818,351
52-Week Range 62.55 - 100.69

More Stats

Market Cap 170.79B
Enterprise Value 196.69B
Earnings Date (est) Jul 31, 2020
Ex-Dividend Date Apr 14, 2020
Shares Outstanding 1.76B
Float 1.47B
EPS (basic) 5.67
EPS (diluted) 5.65
FCF / Share 9.15
Dividend $4.72
Dividend Yield 4.87%
Earnings Yield 5.83%
FCF Yield 7.93%
Payout Ratio 77.40%
Shares Short 19.76M
Short Ratio 1.94
Short % of Float 1.12%
Beta 0.82
PE Ratio 17.15
Forward PE 10.14
P/FCF Ratio 12.60
PS Ratio 5.01
PB Ratio n/a
Revenue 34.06B
Operating Income 13.58B
Net Income 8.44B
Free Cash Flow 13.55B
Net Cash -25.90B
Net Cash / Share -14.70
Gross Margin 75.83%
Operating Margin 39.86%
Profit Margin 24.80%
FCF Margin 39.79%
ROA 11.80%
ROE n/a
ROIC 20.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (16)

Buy 11
Overweight 1
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$107.64*
(11.07% upside)
Low
91.0
Current: 96.91
High
125.0
Target: 107.64
*Average 12-month price target from 14 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue33,26632,75328,21625,63822,85919,96018,79018,38017,44415,638
Revenue Growth1.57%16.08%10.06%12.16%14.52%6.23%2.23%5.37%11.55%-
Gross Profit25,82725,03521,17419,80618,35915,53414,20913,87212,80511,345
Operating Income12,9836,3839,5459,3407,5373,4115,6645,8173,6204,717
Net Income7,8825,6875,3095,9535,1441,7744,1285,2753,4334,178
Shares Outstanding1,4811,5411,5961,6221,6251,5951,5891,5771,577-
Earnings Per Share5.283.663.303.633.131.102.563.352.182.65
EPS Growth44.26%10.91%-9.09%15.97%184.55%-57.03%-23.58%53.67%-17.74%-
Dividend Per Share4.283.592.562.282.021.661.60---
Dividend Growth19.22%40.23%12.28%12.87%21.69%3.75%----
Operating Cash Flow13,32413,4279,9607,0417,5353,5496,2676,3456,2474,976
Capital Expenditures-552-638-529-479-532-612-491-333-356-448
Free Cash Flow12,77212,7899,4316,5627,0032,9375,7766,0125,8914,528
Cash & Equivalents39,9248,0619,7896,4238,4078,3749,8957,9766531,883
Total Debt66,72840,31037,36836,84231,67114,97714,72315,67248.00-
Net Cash / Debt-26,804-32,249-27,579-30,419-23,264-6,603-4,828-7,6966051,883
Assets89,11559,35270,78666,09953,05027,51329,19827,00819,52121,135
Liabilities97,28767,79865,68961,46349,10525,77124,70623,6457,5895,432
Book Value-8,172-8,4465,0974,6363,9451,7424,4923,36311,93215,703
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AbbVie Inc.
Country United States
Employees 30,000
CEO Richard A. Gonzalez

Stock Information

Ticker Symbol ABBV
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NYSE: ABBV

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.